C3 burns treatment gains European acceptance

C3 has announced that its CellSpray and CellSpray XP spray-on skin products have been accepted for use in The Netherlands and Denmark, in one case in an application the company had not previously considered.

The products have been deemed suitable for a range of applications in The Netherlands including burns treatment and plastic surgery and for a very specific use in Denmark through the National Hospital in Copenhagen.

C3 is currently in discussions with the National Hospital, which has expressed an interest in testing CellSpray in selected patients with Necrotising Fasciitis, a type of flesh-eating bacteria.

C3 CEO Troels Jordansen said the company had not considered its spray-on skin products being used for this purpose.

"It is a completely application for us that we have never tried before," he said. "We can now maybe save lives with our technology on other groups of patients."

Mr Jordansen said it was still to be seen whether the products could help patients with the disease.

Subject to the outcome of tests in Denmark and demand for the products in The Netherlands, C3 will supply these markets from its Perth-based laboratory and has already appointed an agent to identify potential business.

Mr Jordansen said biological skin products had not typically been used in the treatment of burns patients in The Netherlands.

"Our hope is that CellSpray’s unique features, clinical results and positive health economical data will meet market needs in The Netherlands and convince surgeons in Copenhagen to adopt CellSpray," he said.

This is not the company’s first foray into the European market.

It has also entered the market in Germany and Austria.

Mr Jordansen said the German and Austrian markets were more significant.

"We know they already use biological skin products," he said.

The company is also close to achieving its good manufacturing practice certificate.

That certificate will allow it to manufacture in the European Union area and most countries in the union will allow the company to sell there.

C3 is also in the process of gaining Food and Drug Administration approval for its products.

In January the company announced to the Australian Stock Exchange that it had "clarified" its FDA regulatory strategy.

That means the company will take longer than it expected to achieve approval for its CellSpray product but possibly less than expected to get its ReCell approved.

On the financial front C3 appears to be going well.  Its share price is hovering around 49 cents.

The company completed a $7 million capital raising last August.

Mr Jordansen said there were no plans to raise any further capital this year.

“It is a completely application for us that we have never tried before.”

-         Troels Jordansen